All In Biotech

Drug Trial Radar · NCT06015243

The Study of Long-term Outcomes of GR1802 in Patients With Chronic Rhinosinusitis With Nasal Polyps

An Open-label, Single-arm, Multicenter, Extension Study to Evaluate the Long-term Safety and Efficacy of GR1802 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps

Last checked: Nov 19, 2026Latest source record: Aug 29, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

70

Planned (sponsor's estimate)

Start

Aug 18, 2023

Primary completion

Dec 30, 2024

Study completion Mar 30, 2025

Sponsor

Sponsor type
Industry
First posted
Aug 29, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, single-arm, multicenter, extension study to evaluate the long-term safety and efficacy of GR1802 injection in patients with Chronic Rhinosinusitis With Nasal Polyps

Conditions

  • Chronic Rhinosinusitis With Nasal Polyps

Interventions

  • GR1802 injectionDrug

    150mg/1ml. 2 ml every two weeks Route of administration: Subcutaneous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse eventsTime frame: Baseline up to Week 24

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.